At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer

Details werden geladen...

At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions

BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

An ASCO preview: What to watch for at cancer research's big meeting | STAT

ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come - BioSpace

At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways

Pfizer Reports Positive Seven-Year Follow-up Data For LORBRENA In Lung Cancer Trial | 29.05.26 | finanzen.ch

Pfizer Reports Positive Seven-Year Follow-up Data For LORBRENA In Lung Cancer Trial | 29.05.26 | finanzen.at

Registrieren

At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer

BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

An ASCO preview: What to watch for at cancer research's big meeting | STAT

ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come - BioSpace

At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways

Pfizer Reports Positive Seven-Year Follow-up Data For LORBRENA In Lung Cancer Trial | 29.05.26 | finanzen.ch

Pfizer Reports Positive Seven-Year Follow-up Data For LORBRENA In Lung Cancer Trial | 29.05.26 | finanzen.at